Takeda Pharmaceutical Company Limited TAK

Full chart Compare
Set alert

Price alert · TAK

All alert types
20.75 USD -0.12 (-0.57%)

At closeNov 3, 2026, 4:00 PM EST

20.75 0.00 0.00%

After hours · Nov 3, 4:00 PM ET

20.71 Day range 20.91
13.50 52-week range 21.22
YTD
+33.10%
1 year
+54.62%
Market cap
66.29B
Revenue (ttm)
4.69T
Profit margin
0.87%
EPS (ttm)
0.07
Shares out
3.19B
P/E ratio
296.43
Forward P/E
39.17
Dividend
0.62 (2.95%)
Ex-dividend date
Mar 30, 2026
YTD return
+33.10%
1-year return
+54.62%
Volume
2.57M
Avg volume
2.73M
Open
20.78
Previous close
20.87
Day's range
20.71 – 20.91
52-week range
13.50 – 21.22
Beta
0.08
Analysts
Strong Buy
Price target
22.90 (+10.4%)
Earnings date
Jan 28, 2027

6M +4.21 (+25.42%)

161820May 21Jun 29Aug 5Sep 10Oct 1520.77

Key statistics

Enterprise value
5.01T
PEG ratio
0.47
Price / sales
0.01
Price / book
1.41
Dividend yield
2.95%
Payout ratio
426.53%
Revenue growth
6.70%
Free cash flow
707.47B
Total cash
418.53B
Total debt
5.36T
Return on equity
0.56%
Short % of float
0.10%
50-day average
18.89
200-day average
17.57

Financials — quick view

All financials
TAK Revenue — quarterly 1.19T
2023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 20262027-Q2 2026
TAK Net income — quarterly 192.46B
2023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 20262027-Q2 2026
TAK EPS — quarterly 60.44
2023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 20262027-Q2 2026

Earnings

TAK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 28, 2027Dec 30, 20260.2818———
Oct 29, 2026Sep 30, 20260.1450.3852+0.24+165.66%
Jul 30, 2026Jun 30, 20260.16890.225+0.06+33.21%
May 13, 2026Mar 31, 20260.21-0.04919-0.26-123.42%
Jan 29, 2026Dec 31, 20250.550.2131-0.34-61.25%
Oct 30, 2025Sep 30, 20250.44-0.02493-0.46-105.67%

Upgrades / downgrades

TAK analyst upgrades and downgrades
DateFirmActionFromTo
May 16, 2023TD CowenmainOutperformOutperform
Apr 4, 2023TD Cowenmain—Outperform
Mar 16, 2023B of A SecuritiesupNeutralBuy
Jul 19, 2022Cowen & Co.upMarket PerformOutperform
Oct 7, 2021Morgan StanleydownOverweightEqual-Weight
Mar 11, 2020JP Morganmain—Overweight

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Japan
Website
takeda.com

News

Your note

Sign in to keep a note on TAK — it syncs with the Stock Master app.

Insider holders

TAK insider holders
InsiderRelationLatest transactionDateShares held
BITETTI TERESA MARIEOfficerSaleAug 9, 2026252,010
DUPREY LAUREN RUSCKOWSKIOfficerSaleSep 13, 2026191,522
FURNEY NATALIE ANNE MARIEOfficerSaleAug 9, 2026204,298
KIM JULIE SO-YOUNGChief Executive OfficerSaleAug 9, 2026391,489
PACHECO RHONDA JANICEOfficerSaleAug 9, 2026182,507
PIGNAGNOLI AGOSTI MARCELLOOfficerSaleAug 9, 2026176,977

Institution ownership

TAK institution ownership
Holder% heldSharesValueReported
Capital Research Global Investors0.60%19,297,680400.62MJun 29, 2026
FMR, LLC0.30%9,599,302199.28MJun 29, 2026
Morgan Stanley0.22%6,994,924145.21MJun 29, 2026
Adage Capital Partners GP L.L.C.0.19%6,050,771125.61MJun 29, 2026
Goldman Sachs Group Inc0.16%5,125,032106.40MJun 29, 2026
Brandes Investment Partners L.P.0.14%4,539,34794.24MJun 29, 2026

Fund ownership

TAK fund ownership
Holder% heldSharesValueReported
AMERICAN MUTUAL FUND0.57%18,157,900376.96MSep 29, 2026
Capital Income Builder0.23%7,343,700152.46MSep 29, 2026
VanEck ETF Trust-VanEck Pharmaceutical ETF0.05%1,538,88831.95MSep 29, 2026
First TRT Exch-Trd Fd.-First TRT Value Line Dividend Index Fd.0.05%1,714,20135.59MSep 29, 2026
Mercer Funds-Mercer Non-US Core Equity Fund0.02%586,09812.17MJun 29, 2026
GOLDMAN SACHS TRUST-Goldman Sachs Income Builder Fund0.02%494,44210.26MJul 30, 2026